Improvement of self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients

Introduction: Patients treated with tiotropium/olodaterol (T/O) show significant improvement in exercise capacity in clinical studies, but real-world data are lacking. Aim: Evaluate perceived limitation with physical functioning (PF), general patient condition and patient satisfaction in stable COPD post treatment with T/O in a real-world setting. Methods: Open-label observational study in 9 Central and Eastern European countries evaluated patients with COPD receiving T/O delivered via Respimat® for 6 weeks. At study start and end, patients completed PF-10 questionnaire and general patient condition was reviewed using the 8-point Physician’s Global Evaluation (PGE) scale. Patient treatment and device satisfaction were assessed at last visit. Results: Based on GOLD 2017, of 7,443 patients enrolled, 48.9% were GOLD B; 24.2% GOLD D; 21.8% GOLD A; and 5.1% GOLD C. Of the 7,218 who completed the study, therapeutic success (10-point increase in PF-101) was achieved in 67.8% (95% CI 66.7–68.8%) of patients, and in 64.3% (95% CI 63.0–65.6%) with infrequent (≤1) and 76.1% (95% CI 74.3–77.9%) with frequent (≥2) exacerbations (p Conclusions: Treatment with tiotropium/olodaterol, under real-life conditions, improved self-reported physical functioning and general condition in patients with COPD.1Mean (SD) at baseline: 46.11 (23.30).